Phase II dose-randomized study of sunvozertinib in platinum-pretreated non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations …
1. 请及时下载文件确认是否正确, 系统将在 2026-06-15 14:30:16 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
JCH Yang, M Wang, L Doucet, Y Fan, D Lv…
Journal of Clinical …, 2025
ascopubs.org
PURPOSE WU-KONG1B (ClinicalTrials. gov identifier: NCT03974022) is a multinational phase II, dose-randomized study to assess the antitumor efficacy of sunvozertinib in pretreated patients with advanced non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins). METHODS Eligible patients with advanced-stage EGFR exon20ins NSCLC were randomly assigned by 1: 1 ratio to receive sunvozertinib 200 mg or 300 mg once daily (200 and 300 mg-rand cohorts) …
